These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 34825870)

  • 41. Epigenetic regulation of mRNA N6-methyladenosine modifications in mammalian gametogenesis.
    Fang F; Wang X; Li Z; Ni K; Xiong C
    Mol Hum Reprod; 2021 May; 27(5):. PubMed ID: 33823008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An Alternatively Spliced Variant of METTL3 Mediates Tumor Suppression in Hepatocellular Carcinoma.
    Xu RY; Ding Z; Zhao Q; Ke TY; Chen S; Wang XY; Wang YY; Sheng MF; Wang W; Long N; Shen YX; Xu YZ; Shao W
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
    Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
    Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification and validation of the N6-methyladenosine RNA methylation regulator ZC3H13 as a novel prognostic marker and potential target for hepatocellular carcinoma.
    Wu S; He G; Liu S; Cao Y; Geng C; Pan H
    Int J Med Sci; 2022; 19(4):618-630. PubMed ID: 35582419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A dynamic reversible RNA N
    Bi Z; Liu Y; Zhao Y; Yao Y; Wu R; Liu Q; Wang Y; Wang X
    J Cell Physiol; 2019 Jun; 234(6):7948-7956. PubMed ID: 30644095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The roles and mechanism of m
    Chen L; He Y; Zhu J; Zhao S; Qi S; Chen X; Zhang H; Ni Z; Zhou Y; Chen G; Liu S; Xie T
    Biomed Pharmacother; 2023 Jul; 163():114839. PubMed ID: 37156113
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of N6-methyladenosine (m
    Elsabbagh RA; Rady M; Watzl C; Abou-Aisha K; Gad MZ
    Cell Commun Signal; 2022 Sep; 20(1):140. PubMed ID: 36085064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. m
    Du K; Zhang L; Lee T; Sun T
    Mol Neurobiol; 2019 Mar; 56(3):1596-1606. PubMed ID: 29909453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Crosstalk between m6A modification and non-coding RNAs in HCC.
    Qiu Z; Yuan X; Wang X; Liu S
    Cell Signal; 2024 May; 117():111076. PubMed ID: 38309550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N
    Fernandez Rodriguez G; Tarullo M; Fatica A
    Cell Mol Life Sci; 2024 Jul; 81(1):326. PubMed ID: 39085650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
    Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aberrant Regulation of mRNA m⁶A Modification in Cancer Development.
    Luo J; Liu H; Luan S; He C; Li Z
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149601
    [No Abstract]   [Full Text] [Related]  

  • 54. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
    Hu Y; Chen J; Liu M; Feng Q; Peng H
    Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. METTL3-mediated m6A methylation of ASPM drives hepatocellular carcinoma cells growth and metastasis.
    Wang A; Chen X; Li D; Yang L; Jiang J
    J Clin Lab Anal; 2021 Sep; 35(9):e23931. PubMed ID: 34398984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. m
    Li W; Liu J; Ma Z; Zhai X; Cheng B; Zhao H
    Dis Markers; 2021; 2021():8859590. PubMed ID: 34234878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
    Wu X; Zhang X; Tao L; Dai X; Chen P
    Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functions of RNA N6-methyladenosine modification in cancer progression.
    Chen B; Li Y; Song R; Xue C; Xu F
    Mol Biol Rep; 2019 Apr; 46(2):2567-2575. PubMed ID: 30911972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer.
    Liu Q
    Front Genet; 2021; 12():825109. PubMed ID: 35087575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.